Business context and reporting period
Nova Measuring Instruments Ltd. filed this Form 20-F annual report for the fiscal year ended December 31, 2015, prepared under U.S. GAAP. Although the request identifies 2015 Q4, the filing presents annual results; it does not provide a clear standalone fourth-quarter income statement or cash-flow figure.
Nova develops metrology systems and software for semiconductor manufacturing. On April 2, 2015, it acquired ReVera for $46.5 million in cash, expanding its thin-film and materials-measurement offerings. ReVera’s results are consolidated from the acquisition date.
Financial results and liquidity
Amounts below are in U.S. dollars; financial-statement figures are rounded to millions.
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $148.5 million | $120.6 million |
| Gross profit / margin | $77.1 million / 51.9% | $63.6 million / 52.7% |
| Operating income / margin | $11.6 million / 7.8% | $16.9 million / 14.0% |
| Net income | $15.7 million | $18.7 million |
| Diluted EPS | $0.57 | $0.67 |
| Operating cash flow | $25.8 million | $33.5 million |
| Cash, cash equivalents and bank deposits | $97.8 million | $123.7 million |
| Working capital | $112.8 million | $130.5 million |
Product revenue was $111.2 million, up 21%; service revenue was $37.3 million, up 31%. Product gross margin was 54%, down from 57%, while service gross margin improved to 44% from 39%. Total operating expenses rose to $65.5 million from $46.7 million, including higher R&D spending, ReVera-related costs and acquired-intangible amortization.
Nova reported no significant long-term debt. Cash and deposits declined by about $25.9 million, principally reflecting the ReVera acquisition, partly offset by operating cash generation. Investing cash flow was an outflow of $9.7 million, including $45.3 million paid for the acquisition, offset in part by reductions in short-term deposits. Capital expenditures were $4.4 million; management expected about $7 million in 2016.
Material changes versus the prior year
- Revenue grew 23%, with management attributing much of the product increase to consolidating ReVera from April 2015; the larger installed base also supported service growth.
- Operating income fell 32% and net income fell 16%, despite revenue growth. Operating margin contracted to 7.8% from 14.0%, reflecting increased operating costs and acquisition-related effects.
- R&D expense rose 35% to $39.7 million, including nine months of ReVera costs; R&D grants offsetting expense were $1.2 million versus $3.5 million in 2014.
- Cash and deposits fell, working capital declined, and inventory increased to $27.7 million from $16.1 million, partly due to ReVera. Inventory write-offs were $2.6 million, compared with $1.6 million.
- Nova repurchased $4.3 million of shares in 2015. The company reported cumulative repurchases of $11.0 million under its $12 million program through February 28, 2016.
Outlook, commentary and risks
Management did not provide a specific 2016 revenue or earnings forecast. It expected semiconductor-equipment spending to be flat or decline slightly, while pursuing growth through advanced-node foundry and memory customers, new products, software, and integration of ReVera’s X-ray technology. Management planned to increase aggregate operating expenses in 2016 and stated that available cash was expected to fund planned activities for at least 12 months.
Industry estimates cited in the filing projected 2016 semiconductor revenue growth of 1.9% and wafer-fab-equipment sales decline of 2.5%. These are third-party industry forecasts, not Nova guidance.
- Customer and product concentration: the five largest customers generated 76% of 2015 revenue; one customer represented 31%. Three product lines remain central to sales.
- Semiconductor-equipment spending is cyclical; quarterly results can vary with order, shipment and revenue-recognition timing. Backlog may not predict sales because customers may delay or cancel orders.
- Competition, rapid technology changes, customer qualification cycles, reliance on process-equipment partners, and limited or single-source suppliers may affect sales and delivery.
- Operations face geographic, currency and facility risks, including exposure to Israel and Asia. More than 90% of cash reserves were held with banks, and over 40% was at one institution.
- The company’s OCS grant-related royalty obligation was approximately $24.0 million at year-end, payable from qualifying future sales; restrictions also apply to certain manufacturing and technology transfers.
- Contractual obligations totaled $25.2 million in the filing’s maturity table. Separately, a note identifies $9.6 million of non-cancelable supplier purchase obligations; the scopes of these disclosures are not clearly reconciled in the filing text.
- The reported 2015 tax benefit was $3.5 million, principally associated with Israeli R&D credits and ReVera-related intangible amortization. The benefit materially supported net income relative to pretax income.
- Financial-statement and internal-control audit opinions were unqualified. However, management’s and the auditor’s 2015 internal-control assessments excluded ReVera, which represented about 14% of consolidated assets and 20% of operating income.
Important facts for investors to verify
- How much of 2015 growth and future performance reflects ReVera versus Nova’s pre-acquisition business, and whether expected integration benefits are being realized.
- Whether customer concentration, especially the 31% customer exposure, has changed since year-end and how orders, cancellations and backlog are trending.
- Why acquisition and integration costs are described as $2.7 million in the operating review but $1.979 million in the acquisition note.
- How the $25.2 million contractual-obligations table relates to the separately disclosed $9.6 million of non-cancelable supplier purchase obligations.
- Whether ReVera controls have been incorporated into Nova’s internal-control assessment, and whether cash concentration, inventory growth and the OCS royalty exposure have changed.